CD7-CAR-T cell therapy (PersonGen Biomedicine)

N/A

Report date: 2024/12/20 10:12:48

Base Information

Drug NameCD7-CAR-T cell therapy (PersonGen Biomedicine)
Drug Alias NameCD7-CART cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[9] 

Other Information

ATC CodeN/A
Related LinksN/A